ResearcherUniversity of KentuckyActive in the last 2 years
Mei Gao
Matched on ORCID iD 0000-0001-8960-8749; OpenAlex author ID A5077864875. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 6
- Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. Co-author DOI 10.1002/1878-0261.70062↗
- Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. Co-author DOI 10.1038/s41467-023-40895-6↗
- Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0270832↗
- Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Co-author DOI 10.3390/cancers14133051↗
- Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-020-0879-6↗
- Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0298-0↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joseph Kim · 6 shared papers, 2019–2025 · strength 0.88
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Megan M. Harper · 3 shared papers, 2022–2025 · strength 0.54
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Michael J. Cavnar · 3 shared papers, 2022–2025 · strength 0.54
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Richard A. Moffitt · 3 shared papers, 2019–2023 · strength 0.34
- Paper Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype. DOI 10.1038/s41467-023-40895-6↗
- Paper Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. DOI 10.1038/s41416-020-0879-6↗
- Paper Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. DOI 10.1038/s41416-018-0298-0↗
- Reema Anil Patel · 2 shared papers, 2022 · strength 0.34
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Hannah G. McDonald · 1 shared paper, 2025 · strength 0.20
- Anna M. Reagan · 1 shared paper, 2025 · strength 0.20
- Jeffrey L. Vacirca · 2 shared papers, 2019–2020 · strength 0.18
- Marcela d'Alincourt Salazar · 2 shared papers, 2019–2020 · strength 0.18
- Minsig Choi · 2 shared papers, 2019–2020 · strength 0.18
- Kenneth Reed Shroyer · 2 shared papers, 2019–2020 · strength 0.18
- Luke A. Torre-Healy · 1 shared paper, 2023 · strength 0.16
- Ki Oh · 1 shared paper, 2023 · strength 0.16
- Scott Powers · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.